ReviewDiabetes therapy : research, treatment and education of diabetes and related disorders2026
Implementing SGLT2 Inhibitor Therapy in Line with the New NICE Guidelines for Type 2 Diabetes Management.
Review in Diabetes therapy : research, treatment and education of diabetes and related disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The latest type 2 diabetes mellitus (T2DM) management guidelines from the UK National Institute for Health and Care Excellence (NICE; NG28) have raised the profile of sodium-glucose cotransporter-2 inhibitors (SGLT2is) so that they are now the preferred first-line therapy in combination with modified-release metformin (or as monotherapy where metformin is contraindicated/not tolerated) for most individuals. Previous NICE recommendations limited use to those with high cardiovascular disease (CVD) risk or existing CVD and/or kidney disease for first-line treatment or people with a need for additional glycaemic optimisation at later stages in the pathway. This change brings the guidelines in line with other national and international recommendations regarding SGLT2i use for the achievement and maintenance of glycaemic targets and lowering of progressive risk for cardiovascular, renal and metabolic (CVRM) complications. Yet, despite a plethora of evidence supporting the role that SGLT2is can play in sustaining long-term health outcomes in people with T2DM, prescribing data from real-world clinical practice show that these therapies are under-prescribed, particularly among those populations most likely to benefit from their use (including individuals with CVD or high CVRM risk). This latest narrative review from the Improving Diabetes Steering Committee examines the place of SGLT2is within the latest NG28 guidelines and likely reasons for suboptimal SGLT2i use, providing pragmatic advice on appropriate approaches to initiation and management in daily practice and setting perceived risks into context against the potential benefits. Practical tools for healthcare professionals and people with T2DM are included, and the Committee's previously published SGLT2i Prescribing Decision Tool for T2DM Management has been updated and aligned with the most recent guidelines with the aim of providing a helpful and high-quality quick reference resource.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.